Abstract

in vitroin vitro at least one target antibody present in an animal serum sample immunised against mosquito extracellular vesicles.

IPC Classes  ?

• A61K 35/56 - Materials from animals other than mammals
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 31/14 - Antivirals for RNA viruses
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 35/64 - Insects, e.g. bees, wasps or fleas
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants

Abstract

1233 are as defined in claim 1.

IPC Classes  ?

• C07F 17/02 - Metallocenes of metals of Groups 8, 9 or 10 of the Periodic Table
• A61K 31/295 - Iron group metal compounds
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Abstract

The invention relates to a portable apparatus (100) for measuring at least one flow of sap in a plant, the plant having an outer casing, the apparatus (100) comprising: - a microwave emitter (10) for emitting a microwave electromagnetic flux towards a first portion of the outer casing of the plant so as to heat an inner portion of the plant; - a thermal sensor (20) arranged to capture thermal radiation from the plant over time; - a processing unit (30) configured to determine, from the thermal radiation captured by the thermal sensor, a movement of the heat front over time in the plant and to estimate, on the basis of the movement of the heat front, the flow of sap.

IPC Classes  ?

• G01F 1/58 - Measuring the volume flow or mass flow of fluid or fluent solid material wherein the fluid passes through a meter in a continuous flow by using electric or magnetic effects by electromagnetic flowmeters
• G01F 1/68 - Measuring the volume flow or mass flow of fluid or fluent solid material wherein the fluid passes through a meter in a continuous flow by using thermal effects
• G01F 1/704 - Measuring the volume flow or mass flow of fluid or fluent solid material wherein the fluid passes through a meter in a continuous flow using marked regions or existing inhomogeneities within the fluid stream, e.g. statistically occurring variations in a fluid parameter
• G01N 25/72 - Investigating presence of flaws
• G01N 22/04 - Investigating moisture content
• G01N 33/00 - Investigating or analysing materials by specific methods not covered by groups

Abstract

CorynebacteriumCorynebacterium, which can be used for a cosmetic application. Also proposed is a method for screening anti-aging substances.

IPC Classes  ?

• C07K 14/195 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A61K 8/99 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
• A61K 35/74 - Bacteria
• A61Q 19/00 - Preparations for care of the skin
• A61Q 19/02 - Preparations for care of the skin for chemically bleaching or whitening the skin
• A61Q 19/08 - Anti-ageing preparations
• C12N 1/20 - BacteriaCulture media therefor
• C12N 15/09 - Recombinant DNA-technology
• C12N 15/74 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
• C12P 1/04 - Preparation of compounds or compositions, not provided for in groups , by using microorganisms or enzymesGeneral processes for the preparation of compounds or compositions by using microorganisms or enzymes by using bacteria
• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms
• C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria

Abstract

The present disclosure relates to methods for treating infectious disorders. In particular, the disclosure provides BTN3A activating antibodies, and their use in treating infectious disorders in a human subject in need thereof, such as disorders caused by SARS-Cov2 or Coxiella burnetii infection.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 31/04 - Antibacterial agents
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The invention relates to the detection of the risk for a patient with a congenital Long QT (LQT) condition for having a torsades-de-pointes event, and the mechanisms underlying such risk, in particular via the use of neural networks.

IPC Classes  ?

• A61B 5/346 - Analysis of electrocardiograms

Abstract

The present invention relates to a compound of the formula (I): (I). The present invention further relates to the process for extracting it, to the medicament or pharmaceutical composition containing it and to its use in therapy, in particular in the prevention and/or treatment of cancer and virus infections.

IPC Classes  ?

• A61P 35/00 - Antineoplastic agents
• A61K 38/00 - Medicinal preparations containing peptides
• C07K 7/64 - Cyclic peptides containing only normal peptide links

Abstract

Disclosed is the use of a compound with the following formula (I): Disclosed is the use of a compound with the following formula (I): Disclosed is the use of a compound with the following formula (I): R is a linear or branched alkyl group including from 2 to 20 carbon atoms, the compound being in the form of a racemic mixture, an enantiomer (R) or an enantiomer (S), as an attractant or repellent for blood-sucking, biting invertebrates.

IPC Classes  ?

• A01N 43/16 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom with one hetero atom six-membered rings with oxygen as the ring hetero atom
• A01P 17/00 - Pest repellants
• A01P 19/00 - Pest attractants

Abstract

The present invention relates to new thermophilic anaerobic bacteria strains to produce hydrogen gas in acidic conditions and a method for producing hydrogen by culturing these thermophilic bacteria strains.

IPC Classes  ?

• C12P 3/00 - Preparation of elements or inorganic compounds except carbon dioxide
• C12R 1/01 - Bacteria or actinomycetales
• C12N 1/20 - BacteriaCulture media therefor

Abstract

The present application relates to a method for the on-line and real-time automatic determination of the oxidization potential of an environment, enabling the air quality and/or the toxicity of the vapors emitted by various appliances or facilities to be analyzed. The present application relates to a method for the on-line and real-time automatic determination of the oxidization potential of an environment, enabling the air quality and/or the toxicity of the vapors emitted by various appliances or facilities to be analyzed. Figure for the abstract: None

IPC Classes  ?

• G01N 33/497 - Physical analysis of biological material of gaseous biological material, e.g. breath

Goods & Services

Education; training; entertainment; sporting and cultural activities; information with respect to entertainment; information with respect to education; vocational retraining; tutoring; organization and conducting of workshops [training]; book publishing and lending of books, magazines and teaching material; electronic publishing of books, periodicals and teaching material online; providing non-downloadable films via video-on-demand services; news reporter services; production of motion pictures, of videos; photography services; organization of competitions (education or entertainment); organization and conducting of colloquiums; organization and conducting of conferences; organization and conducting of congresses; organization of exhibitions for cultural or educational purposes; electronic publication of books and journals online. Technical evaluations concerning design (engineers' services); scientific research; research in natural sciences and in earth sciences; technical research; conducting of technical project studies; quality control; scientific and technical expertise; design of computers for third parties; computer development; design, development and implementation of software; computer system analysis; computer system design; consultant services with respect to computer hardware design and development; digitization of documents; Software as a Service (SaaS); advice regarding information technology; server hosting; energy auditing; electronic data storage; research and development of new products for third parties.

Abstract

Coronaviridae is a family of enveloped, positive-sense, single-stranded RNA viruses. The emergence of a new beta-coronavirus SARS-CoV-2 has led to a major health-related crisis associated with a significant mortality in intensive care units, due to the pulmonary complications of COVID-19. The inventors showed that BAY-2402234 is suitable for inhibiting replication of coronavirus and thus would be suitable for the treatment of infections mediated by said type of virus.

IPC Classes  ?

• A61K 31/4196 - 1,2,4-Triazoles
• A61K 38/21 - Interferons
• A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
• A61K 31/4706 - 4-Aminoquinolines8-Aminoquinolines, e.g. chloroquine, primaquine

Abstract

Coronaviridae is a family of enveloped, positive-sense, single-stranded RNA viruses. The emergence of a new betacoronavirus SARS-CoV-2 has led to a major health-related crisis associated with a significant mortality in intensive care units, due to the pulmonary complications of COVID-19. The inventors showed that Vidofludimus is suitable for inhibiting replication of coronavirus and thus would be suitable for the treatment of infections mediated by said type of virus.

IPC Classes  ?

• A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
• A61P 31/14 - Antivirals for RNA viruses
• A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine

Abstract

The present disclosure relates to methods for treating infectious disorders. In particular, the disclosure provides BTN3A activating antibodies, and their use in treating infectious disorders in a human subject in need thereof, such as disorders caused by SARS-Cov2 or Coxiella burnetii infection.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 31/04 - Antibacterial agents
• A61P 31/14 - Antivirals for RNA viruses

Abstract

616-6441138-11691138-1169616-644616-6441138-1169616-6441138-11691138-1169 have ability to react as antibody epitopes in relation to a BNT162b2 recipient serum and thus can be used for diagnostic and vaccine purposes.

IPC Classes  ?

• C07K 14/165 - Coronaviridae, e.g. avian infectious bronchitis virus
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus

Abstract

A protein hydrolysate obtained from at least one protein source from bluefish having (i) a degree of hydrolysis (DH) of at least 10%, (ii) at least 80% water-soluble protein with a molecular weight of less than 1000 Da, (iii) at least 0.3% phospholipids, and (iv) at least 0.5% DHA and EPA.

IPC Classes  ?

• A23J 1/04 - Obtaining protein compositions for foodstuffsBulk opening of eggs and separation of yolks from whites from fish or other sea animals
• A23J 3/04 - Animal proteins
• A23J 3/34 - Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes
• A23K 20/147 - Polymeric derivatives, e.g. peptides or proteins
• A23K 50/40 - Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
• A23L 33/115 - Fatty acids or derivatives thereofFats or oils
• A23L 33/12 - Fatty acids or derivatives thereof
• A23L 33/18 - PeptidesProtein hydrolysates
• A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
• A61K 35/60 - Fish, e.g. seahorsesFish eggs
• A61K 38/01 - Hydrolysed proteinsDerivatives thereof

Abstract

The present invention relates to the use of a compound of formula (I) where R represents a linear or branched alkyl group comprising from 2 to 20 carbon atoms, said compound being in the form of a racemic mixture, of an enantiomer (R) or an enantiomer (S), as an attractant or repellent for blood-sucking, biting invertebrates.

IPC Classes  ?

• A01N 43/16 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom with one hetero atom six-membered rings with oxygen as the ring hetero atom
• A01P 17/00 - Pest repellants
• A01P 19/00 - Pest attractants

Abstract

The invention relates to methods and devices for the detection and prediction of the risk for a patient to have a torsade de pointe event, and causes thereof, in particular via the use of neural networks.

IPC Classes  ?

• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment

Abstract

The present invention relates to a complex of cationic or neutral gold (I) with fluorinated NHC ligands, as well as the uses thereof as an anti-oxidant, anti-cancer, anti-bacterial and/or anti-parasitic agent and, in particular, an anti-leishmanial agent.

IPC Classes  ?

• C07F 1/00 - Compounds containing elements of Groups 1 or 11 of the Periodic Table
• A61P 35/00 - Antineoplastic agents
• C07H 23/00 - Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12

Abstract

ZikaApoptosis M PeptideApoptosis M Peptide) (SEQ ID NO:l) to confer pro-apoptotic activity to a tumor-associated antigen such as MPF opens up new attractive perspectives for ZAMP as innovative anti-cancer agent.

IPC Classes  ?

• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• A61K 38/08 - Peptides having 5 to 11 amino acids
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• C07K 19/00 - Hybrid peptides
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• A61P 35/00 - Antineoplastic agents

Abstract

The present application relates to a method for the on-line and real-time automatic determination of the oxidization potential of a medium, enabling the air quality and/or the toxicity of the vapors emitted by various appliances or facilities to be analyzed.

IPC Classes  ?

• G01N 33/84 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving inorganic compounds or pH

Goods & Services

Scientific measuring apparatus and instruments; connected environmental-measurement station particularly for measuring air quality, humidity levels and temperature; air analysis apparatus; hygrometers; thermo-hygrometers; meteorological instruments; digital weather stations; air quality micro-sensor; humidity micro-sensor; temperature micro-sensor; environmental measurement micro-sensors; apparatus and instruments for data recording, transmission, reproduction or processing; software [recorded programs] for use in environmental-measurement stations; downloadable electronic publications. Providing access to databases; data dissemination and transmission services by electronic means. Education; training; organization and conducting of training workshops; organization and conducting of conferences; practical training [demonstration]; organization and conducting of non-virtual educational forums; providing information with respect to education; publication of texts other than advertising texts; online publication of specialized electronic journals; providing non-downloadable electronic publications online. Scientific and technological services as well as research and design services relating thereto; conducting of technical project studies; surveying [engineering work]; providing software for collecting data concerning air quality; air quality assessment, monitoring and analysis services; research and providing scientific information in the field of climate change; computer platform as a service [PaaS].

Abstract

The present invention relates to the use of carnosol or of a composition comprising carnosol for increasing muscle protein synthesis and/or for reducing the muscle protein degradation in a subject.

IPC Classes  ?

• A61K 31/366 - Lactones having six-membered rings, e.g. delta-lactones
• A61P 21/06 - Anabolic agents

Abstract

CoronaviridaeCoronaviridae is a family of enveloped, positive-sense, single-stranded RNA viruses. The emergence of a new betacoronavirus SARS-CoV-2 has led to a major health-related crisis associated with a significant mortality in intensive care units, due to the pulmonary complications of COVID-19. The inventors showed that BAY-2402234 is suitable for inhibiting replication of coronavirus and thus would be suitable for the treatment of infections mediated by said type of virus.

IPC Classes  ?

• A61K 31/4196 - 1,2,4-Triazoles
• A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
• A61K 31/4706 - 4-Aminoquinolines8-Aminoquinolines, e.g. chloroquine, primaquine
• A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 31/14 - Antivirals for RNA viruses
• A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
• A61K 38/21 - Interferons

Abstract

CoronaviridaeCoronaviridae is a family of enveloped, positive-sense, single-stranded RNA viruses. The emergence of a new betacoronavirus SARS-CoV-2 has led to a major health-related crisis associated with a significant mortality in intensive care units, due to the pulmonary complications of COVID-19. The inventors showed that Vidofludimus is suitable for inhibiting replication of coronavirus and thus would be suitable for the treatment of infections mediated by said type of virus.

IPC Classes  ?

• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61P 31/20 - Antivirals for DNA viruses

Abstract

Lung infections remain a substantial concern, even in wealthy countries. For instance, the emergence of a new betacoronavirus SARS-CoV-2 has led to a major health-related crisis associated with a significant mortality in intensive care units, due to the pulmonary complications of COVID-19. The inventors aim at developing a new therapeutic approach based on the local delivery of apolipoprotein A1 nanoparticles into the lung by aerosolization. These particles may display antiviral properties that could be improved by loading them with small interference RNAs specifically targeting SARS-CoV2 genome and antiviral drugs (such as the hydrophobic chloroquine). Their preliminary results have shown in preclinical mouse models that aerosolization allowed apoA1 nanoparticle uptake and persistence (up to 72h) in pulmonary cells. In addition to the potential intrinsic antiviral activity of apoA1, these particle display important anti-inflammatory effects that may limit the excessive immuno-inflammatory host response that is deleterious for the lung. Thus, the present invention relates to aerosolization of HDL for the treatment of lung infections.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 31/661 - Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• A61P 31/06 - Antibacterial agents for tuberculosis
• A61P 31/12 - Antivirals
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses

Abstract

The present invention relates to the field of vaccination against flaviviruses, and in particular against Zika virus. The invention further relates to methods for producing or selecting antibodies directed against said flaviviruses. The invention further relates to isolated polypeptides, recombinant cells, and attenuated viruses, suitable for eliciting an immune response. The inventors have shown that a 20-mer peptide GSQHSGMTVNDIGYETDENR representing the glycan-loop (GL) of the Zika virus (ZIKV) strain MR766 is antigenic in a peptide-based ELISA format. To the knowledge of the inventors, this is the first report demonstrating the antigenicity of a fragment of the Envelope protein of a flavivirus, within Domain I (E-DI), which explicitly includes the glycan-loop itself.

IPC Classes  ?

• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• A61K 39/12 - Viral antigens

Abstract

Leishmania as well as to pharmaceutical compositions and vaccines for use against one or more leishmaniases.

IPC Classes  ?

• A61K 39/008 - Leishmania antigens
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The invention relates to the use of taxodione to inhibit protein glycation.

IPC Classes  ?

• A61Q 19/08 - Anti-ageing preparations
• A61K 8/35 - Ketones, e.g. quinones, benzophenone
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61P 17/00 - Drugs for dermatological disorders

Abstract

The invention relates to a protein hydrolysate which is obtained from at least one protein source derived from blue-backed fish and which comprises (i) a degree of hydrolysis (DH) of at least 10%, (ii) at least 80% water-soluble proteins having a molecular weight of less than 1000 Da, (iii) at least 0.3% phospholipids, and (iv) at least 0.5% DHA and EPA.

IPC Classes  ?

• A23K 20/147 - Polymeric derivatives, e.g. peptides or proteins
• A23J 3/34 - Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes
• A23K 50/40 - Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
• A23L 33/18 - PeptidesProtein hydrolysates
• A61K 38/01 - Hydrolysed proteinsDerivatives thereof
• A23L 33/115 - Fatty acids or derivatives thereofFats or oils
• A23L 33/12 - Fatty acids or derivatives thereof
• A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
• A23J 3/04 - Animal proteins

Abstract

The invention relates to methods and devices for the detection and prediction of the risk for a patient to have a torsade de pointe event, and causes thereof, in particular via the use of neural networks.

IPC Classes  ?

• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

The present invention relates to compound of formula (I): 3 or for use in prevention and/or treatment of a disease or disorder linked to an exacerbated vascular, lymphatic or mucosal permeability.

IPC Classes  ?

• A61K 31/235 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group

Abstract

The invention relates to the field of glaciology and more particularly to a device (1) for measuring the surface melting of a glacier, comprising: - a measurement module for measuring the surface melting of the glacier; - a remote transmission system; - a support; and - a battery; characterized in that the measurement module comprises a cable (110), a winder capable of winding the cable (110) so as to keep said cable taut, an encoder wheel configured so as to be rotated when the cable is wound by the winder; the winder and the encoder wheel being arranged such that the surface melting of the glacier causes the cable to be wound by the winder and the encoder wheel to rotate correspondingly; the remote transmission system then being capable of transmitting a measured signal proportional to the surface melting of the glacier.

IPC Classes  ?

• G01W 1/14 - Rainfall or precipitation gauges
• G01W 1/02 - Instruments for indicating weather conditions by measuring two or more variables, e.g. humidity, pressure, temperature, cloud cover or wind speed

Abstract

The present invention relates to the use of carnosol or of a composition comprising carnosol for increasing muscle protein synthesis and/or for reducing the muscle protein degradation in a subject.

IPC Classes  ?

• A61K 31/366 - Lactones having six-membered rings, e.g. delta-lactones
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 21/06 - Anabolic agents
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system

Abstract

1122333' are cationic or hydrophobic residues.

IPC Classes  ?

• C07K 7/02 - Linear peptides containing at least one abnormal peptide link
• C07K 5/02 - Peptides having up to four amino acids in a fully defined sequenceDerivatives thereof containing at least one abnormal peptide link
• C07D 277/56 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 31/00 - Medicinal preparations containing organic active ingredients

Abstract

The present invention relates to the abietane diterpene taxodione and to rosemary stem extract containing taxodione for their use in treating a muscle wasting diseases and/or disorders; it also relates to the use of taxodione as natural meat preserver.

IPC Classes  ?

• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A23L 3/3499 - Organic compounds containing oxygen with doubly-bound oxygen
• A61K 36/53 - Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
• A61K 36/537 - Salvia (sage)
• A23K 20/111 - Aromatic compounds
• A23K 20/10 - Organic substances
• A23L 13/40 - Meat productsMeat mealPreparation or treatment thereof containing additives
• A23L 15/00 - Egg productsPreparation or treatment thereof
• A23L 17/00 - Food-from-the-sea productsFish productsFish mealFish-egg substitutesPreparation or treatment thereof

Abstract

LeishmaniaLeishmania as well as to pharmaceutical compositions and vaccines for use against one or more leishmaniases.

IPC Classes  ?

• A61K 39/008 - Leishmania antigens

Abstract

The object of the present invention is a device (1) for the observation and in situ characterisation of a sample (2) subjected to very high pressure and heated to a temperature of between 1300K and 1900K, comprising a DAC (3) with diamond anvils (31, 32) arranged on seats (51, 52) which is resistant to high pressure and serves as a high temperature thermal insulator, wherein said DAC (3) is associated with an inductive heating mode (7) having at least one coil (730).

IPC Classes  ?

• G01N 21/03 - Cuvette constructions
• B01L 7/00 - Heating or cooling apparatusHeat insulating devices
• B01J 3/06 - Processes using ultra-high pressure, e.g. for the formation of diamondsApparatus therefor, e.g. moulds or dies
• G01N 23/20041 - Sample holders or supports therefor for high pressure testing, e.g. anvil cells

Abstract

Flaviviruses are largely pathogenic to humans and other mammals and mostly are transmitted by mosquitoes. To combat flavivirus infections, it is urgent to propose safe and effective anti-viral compounds not only to impair the virus spread but also to mitigate the associated morbidities. Despite the development of antiviral agents from synthetic sources, a novel antiviral approach (economical, simple and environmentally friendly) is to use natural sources such as nutraceutical as preventive treatments against viral infections. The inventors demonstrated that flavonoid isoquercitrin exerts antiviral activity against African historical and Asian epidemic strains of ZIKV in human hepatoma, epithelial and neuroblastoma cell lines. They showed that isoquercitrin acts on ZIKV entry by preventing the internalization of virus particles into the host cell. Next the inventors demonstrated that Q3G exert antiviral activity against Yellow Fever Virus (YFV). These results suggest that Q3G represents a potential prophylactic agent targeting the entry of two medically relevant flavivirus and could thus be used to prevent flavivirus infection. Accordingly, the the present invention relates to use of quercetin-3 -O-glucoside for the treatment of flavivirus infections.

IPC Classes  ?

• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The present invention relates to vaccine compositions comprising an attenuated mutant Zika virus. The inventors have introduced mutations at very specific positions that abrogate the N-glycosylation site on the E protein of the epidemic strain which will prevent the generation of auto-antibodies responsible for Guillain-Barre syndrome. The inventors have also produced additional mutations of the virus that result to a dramatic reduction of the cytopathic effects without affecting the capacity to produce high titers of virus. In particular, the present invention relates to an attenuated mutant Zika virus comprising a protein E of the epidemic strain wherein at least one amino acid residue at position 152, 156 or 158 is mutated.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/12 - Viral antigens
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 35/76 - VirusesSubviral particlesBacteriophages
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The present invention concerns a method for isolating an archaebacterium of order Methanomassiliicoccales of the commensal clade, the use of a culture and/or isolation medium comprising a sterile extract of a bacterial culture of a bacterium of the Eggerthella genus, for isolating and/or culturing an archaebacterium of order Methanomassiliicoccales of the commensal clade, and a pure isolated Methanomethylophilus alvus Mx-05 archaebacterium. It also concerns a method for culturing an archaebacterium of order Methanomassiliicoccales of the commensal clade.

IPC Classes  ?

• C12N 1/20 - BacteriaCulture media therefor
• C12R 1/01 - Bacteria or actinomycetales

Abstract

31216121112112161121112121)alkenyl group, or its pharmaceutically acceptable salts, racemates, diastereoisomers, enantiomers, or mixtures thereof, for use in prevention and/or treatment of a disease or disorder linked to an exacerbated vascular, lymphatic or mucosal permeability.

IPC Classes  ?

• A61K 31/23 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
• A61K 31/231 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
• A61K 31/232 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
• C07C 69/22 - Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
• C07C 69/587 - Monocarboxylic acid esters having at least two carbon-to-carbon double bonds
• A61P 9/14 - VasoprotectivesAntihaemorrhoidalsDrugs for varicose therapyCapillary stabilisers

Abstract

The invention relates to a device for fermentation in solid medium, comprising a basal portion (10) forming a ventilation system, and a fermentation chamber (20) formed on the basal portion (10), the basal portion (10) comprising a plurality of ventilation openings (110) towards the fermentation chamber (20) and at least one inlet opening (12) intended for being connected to a gas source, the fermentation chamber (20) comprising at least one outlet opening (21) allowing a discharge of gas contained in said fermentation chamber (20), characterised in that the basal portion (10) and the fermentation chamber (20) are made of the same flexible material, the basal portion (10) being formed from a plurality of ventilation channels (11) arranged parallel to one another through which the plurality of ventilation openings (110) towards the fermentation chamber (20) are formed, a micro-perforated screen (30) also being attached to the basal portion (10) arranged on the ventilation channels (11) between the ventilation openings (110) and the fermentation chamber (20).

IPC Classes  ?

• C12M 1/16 - Apparatus for enzymology or microbiology containing, or adapted to contain, solid media
• C12M 1/00 - Apparatus for enzymology or microbiology

Abstract

Disclosed is a device for detecting at least one chemical species in a medium to be analyzed including a chemical sensor, the chemical sensor including: a substrate; a functionalized carrier intended for capturing and accumulating the chemical species and attached to a side of the substrate. The device also includes a unit for diffusion between the medium to be analysed and the functionalised carrier. The diffusion unit includes a vibration generating system connected to the chemical sensor in order to subject the chemical sensor to controlled vibrations.

IPC Classes  ?

• G01N 1/10 - Devices for withdrawing samples in the liquid or fluent state
• G01N 33/18 - Water
• B05D 1/00 - Processes for applying liquids or other fluent materials
• B05D 1/18 - Processes for applying liquids or other fluent materials performed by dipping

Abstract

The present invention relates to a genomic sequences encoding for an attenuated mutant Zika virus. The inventors have introduced some specific substitutions at very specific positions in the epidemic genomic sequence for restoring some fixation sites for miR-4279 that were originally present in the endemic genomic sequence. Moreover the inventors have additionally introduced mutation leading to the abrogation of the N-glycosylation site on the E protein which will prevent the generation of auto-antibodies responsible for Guillain-Barre syndrome. The inventors have produced additional mutations of the virus that result to a dramatic reduction of the cytopathic effects without affecting the capacity to produce high titers of virus. In particular the present invention relates to a genomic sequence characterized by the sequence represented by SEQ ID NO:1 wherein at least one site of fixation for miR-4279 is restored.

IPC Classes  ?

• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C12N 7/04 - Inactivation or attenuationProducing viral sub-units
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The present invention relates to vaccine compositions comprising an attenuated mutant Zika virus. The inventors have introduced mutations at very specific positions that abrogate the N-glycosylation site on the E protein of the epidemic strain which will prevent the generation of auto-antibodies responsible for Guillain-Barre syndrome. The inventors have also produced additional mutations of the virus that result to a dramatic reduction of the cytopathic effects without affecting the capacity to produce high titers of virus. In particular, the present invention relates to an attenuated mutant Zika virus comprising a protein E of the epidemic strain wherein at least one amino acid residue at position 152, 156 or 158 is mutated.

IPC Classes  ?

• A61K 39/12 - Viral antigens

Abstract

The present invention concerns a process for the co-culture of an anaerobic mesophilic bacterium pertaining to the genus Mesotoga with at least one hydrogenotrophic sulfate-reducing bacterium.

IPC Classes  ?

• C12P 1/04 - Preparation of compounds or compositions, not provided for in groups , by using microorganisms or enzymesGeneral processes for the preparation of compounds or compositions by using microorganisms or enzymes by using bacteria
• B09C 1/00 - Reclamation of contaminated soil
• B09C 1/10 - Reclamation of contaminated soil microbiologically or by using enzymes
• C02F 3/28 - Anaerobic digestion processes
• C02F 3/34 - Biological treatment of water, waste water, or sewage characterised by the microorganisms used
• C12P 7/54 - Acetic acid
• C12P 3/00 - Preparation of elements or inorganic compounds except carbon dioxide

Abstract

The present invention relates to methods and compositions for preventing, treating and diagnosing infection by trypanosomes. The invention also relates to the use of excreted/secreted antigens (exoantigens, secretome) and specifically to the identification of a protein excreted/secreted by the trypanosomes, the inhibition of which makes it possible to provide effective protection, mainly by vaccination, against infection by trypanosomes or the development or spread thereof. The invention relates to use of the protein, the derivatives thereof, a nucleotide sequence derived from said protein, or an extract enriched with said protein, and to the use of antibodies directed against said trypanosomes for immunotherapy, diagnosis, and monitoring of infections by trypanosomes.

IPC Classes  ?

• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61K 39/005 - Trypanosoma antigens
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• A61P 33/02 - Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis

Abstract

The present invention relates to novel antimicrobial peptides, pharmaceutical compositions comprising said peptides, and the uses thereof, in particular as antimicrobial drugs, disinfectants, pesticides or preservatives. The present invention also relates to a transgenic plant expressing said novel peptides.

IPC Classes  ?

• C07K 14/46 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates
• A61K 38/00 - Medicinal preparations containing peptides

Abstract

The present invention relates to methods for on demand pre-exposure prophylactic treatment of HIV infection. In particular, the present invention relates to a method for on demand pre-exposure prophylactic treatment of a subject at substantial risk for HIV infection comprising administering orally the subject with a combination of a therapeutically effective amount of emtricitabine and tenofovir prior and after to exposure to a potential source of HIV.

IPC Classes  ?

• A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• A61P 31/18 - Antivirals for RNA viruses for HIV

Abstract

The invention relates to a device (1) for detecting at least one chemical species in a medium to be analyzed. Said device includes a chemical sensor (2). The chemical sensor (2) includes: - a substrate (4); and - a functionalized carrier (5) intended for detecting and accumulating the chemical species and attached to a surface of the substrate (4). The device also includes means for diffusion between the medium to be analyzed and the functionalized carrier (5). The device (1) is characterized in that the diffusion means include a vibration generating system (3) connected to the chemical sensor (2) in order to subject the chemical sensor (2) to controlled vibrations.

IPC Classes  ?

• G01N 1/10 - Devices for withdrawing samples in the liquid or fluent state
• G01N 33/18 - Water
• G01N 33/551 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals the carrier being inorganic
• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals

Abstract

The invention concerns a system and a method for the automated identification of haematophagous Diptera that are vectors of infectious diseases. The system according to the invention comprises: - a database containing reference image data of wings of a plurality of species of haematophagous Diptera that are vectors of infectious diseases, said image data being obtained from optical interference patterns of said wings; a portable device comprising means for acquiring images of a wing removed from a captured Diptera specimen; - a support for holding the wing removed from the captured Diptera specimen; - means for transmitting image data of the removed wing to the database; and - means for comparing the image data of the removed wing with the reference image data of the database and for identifying the captured Diptera with a view to determining if said Diptera is a haematophagous Diptera that is a vector of infectious diseases. The invention applies to the identification of haematophagous Diptera that are vectors of infectious diseases.

IPC Classes  ?

• G06F 19/00 - Digital computing or data processing equipment or methods, specially adapted for specific applications (specially adapted for specific functions G06F 17/00;data processing systems or methods specially adapted for administrative, commercial, financial, managerial, supervisory or forecasting purposes G06Q;healthcare informatics G16H)

Abstract

The invention concerns a method for counting aquatic species passing through a container (1, 2, 3) provided with a camera (7) having a field of view, said method comprising a step of acquiring images originating from said camera, and a measurement step during which the objects appearing on an image are measured. The method is remarkable in that it further comprises a marking step in order to associate each object with the length of same, a monitoring step for monitoring the progress of an object in said container by means of successive images, a counting step for incrementing a counter by one unit when an object has left the field of the camera (7), or in other words when it no longer appears on the current image.

IPC Classes  ?

• G06M 11/00 - Counting of objects distributed at random, e.g. on a surface
• G06M 1/10 - Design features of general application for actuating the drive by electric or magnetic means
• A01K 61/00 - Culture of aquatic animals
• G06T 7/00 - Image analysis

Abstract

Leishmania, especially infection with a South American strain causing the American Tegumentary Leishmaniasis (ATL).

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

The present invention relates to a fabaceae/gramineae plant combination, inoculated with symbiotic microorganisms. The plant combination may be in the form of seeds or in the form of strips of turf. The invention also relates to the use of the plant combination for turfing urban environments with strong water and thermal constraints and the grassing of vineyards and orchards.

IPC Classes  ?

• A01G 1/00 - Horticulture; Cultivation of vegetables (labels or name-plates G09F 3/00, G09F 7/00)

Abstract

6) alkyl group. The invention also relates to the method for preparing said compound, to a pharmaceutical composition containing same, and to the use thereof as a drug, particularly for cancer treatment.

IPC Classes  ?

• C07H 17/08 - Hetero rings containing eight or more ring members, e.g. erythromycins
• C07H 1/08 - SeparationPurification from natural products

Abstract

The invention relates to a novel hyperhalophilic strain and the use thereof for the degradation of carbon substrates, allowing, in particular, the production of novel polymers.

IPC Classes  ?

• C12N 1/20 - BacteriaCulture media therefor
• C12P 7/62 - Carboxylic acid esters
• C12R 1/01 - Bacteria or actinomycetales

Abstract

The invention relates to immunogenic peptide, characterized in that it consists of 15 to 25 amino acids of an EBOV protein and that it comprises a sequence of 15 aminoacids selected in the group comprising sequences SEQ ID N° 1 - 61.

IPC Classes  ?

• A61K 39/12 - Viral antigens

Abstract

useful as probes to detect and quantify all HIV-1 circulating forms and their precursors SIVcpz/SIVgor.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
• C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage

Abstract

The present invention relates to the use of 4-phenylbutyric acid, or one of the salts thereof, for improving the resistance of plants to harmful biological organisms, in particular to bacteria, viruses and nematodes, and for inhibiting hypersensitive cell death induced by such harmful biological organisms. The present invention also relates to the use of 4-phenylbutyric acid, or one of the salts thereof, as an antimicrobial agent for preventing or treating plant diseases caused by phytopathogens.

IPC Classes  ?

• A01N 37/10 - Aromatic or araliphatic carboxylic acids, or thio-analogues thereofDerivatives thereof

Abstract

The invention relates to a pharmaceutical composition intended for use in the prevention and/or treatment of leukaemia in a subject, said composition comprising palytoxin (PLTX) and a pharmaceutically acceptable carrier. The application also relates to other medical uses of palytoxin and a method for its extraction from Palythoa clavata polyps. It is also described a method for isolating the symbiodinium dinoflagellate from Palythoa clavata.

IPC Classes  ?

• C12N 1/12 - Unicellular algaeCulture media therefor
• C07D 493/08 - Bridged systems
• A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
• A61P 35/02 - Antineoplastic agents specific for leukemia
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• A61P 17/00 - Drugs for dermatological disorders
• A61P 33/00 - Antiparasitic agents

Abstract

The invention relates to the use, as a vaccine molecule in a mammal, of a PSA, such as a Leishmania PSA, or a part of said PSA having immunogenic properties. Said PSA, hereinafter referred to as "ES PSAr", is in a soluble, native, recombinant form. The invention also relates to a vaccine composition for preventing and/or treating Leishmaniases containing an ES PSAr protein.

IPC Classes  ?

• C07K 14/44 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from protozoa
• A61K 39/008 - Leishmania antigens

Abstract

A unit for measuring the falling speed of particles in suspension in a fluid comprises a sealed container (6) having an opening (9) and defining an open compartment (15) comprising the opening and intended to contain the fluid, and a sealed compartment (16), sealing means separating the open compartment from the sealed compartment, and means for measuring the falling speed placed in the sealed compartment and comprising at least three electromagnetic radiation emitters distributed along a longitudinal axis (L) of the open compartment, each emitter being oriented according to a radiation axis crossing the open compartment at different heights along the longitudinal axis, an equal number of receivers distributed along the longitudinal axis, each receiver being placed in the radiation axis of a corresponding emitter, means for controlling the emitters and the receivers, and a system for acquiring data connected to the receivers, the acquired data being used to obtain the falling speed of the particles and the change of same as a function of the height in the open compartment and as a function of time, said change quantifying the flocculation of the particles.

IPC Classes  ?

• G01N 15/04 - Investigating sedimentation of particle suspensions
• G01N 15/00 - Investigating characteristics of particlesInvestigating permeability, pore-volume or surface-area of porous materials
• G01N 21/59 - Transmissivity

Abstract

The invention concerns a counting device (1) for counting elements (W, X, Y, Z) during an analysis consisting of recognising and counting at least one type (3w, 3x, 3y, 3z) of defined material element in a defined material medium (3), the counting of the elements of the defined type resulting from observations, in particular visual observations, of a human operator (2) in a predefined observation field (4) of the medium (3) that can contain said elements (W, X, Y, Z), said observations consisting, for the operator, of visually recognising the elements of the defined type or types and the counting consisting, for the operator, of incrementing (5, 5'), by one, a counter (10, 10') of the counting device for counting elements of the corresponding type each time an element of said defined type that has not yet been counted is recognised, said element counter comprising a means (5, 5') of incrementing per type of element. According to the invention, the counting device further comprises a means (9) for measuring time and means for combining at least one item of time data with the incrementations, the counting device comprising electronic circuits having a microprocessor programmed with memory for storing the counting data and time data. A calculation means makes it possible to use the incrementation and time data to determine a result of the analysis of said data by calculation.

IPC Classes  ?

• G04F 1/00 - Apparatus which can be set and started to measure-off predetermined or adjustably-fixed time intervals without driving mechanisms, e.g. egg timers
• C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters
• G06M 1/00 - Design features of general application

Abstract

The present invention relates to novel antimicrobial peptides, to pharmaceutical compositions comprising said peptides,and to the uses thereof, in particular as antimicrobial drugs, disinfectants, pesticides or preservatives. The present invention also relates to a transgenic plant expressing said novel peptides.

IPC Classes  ?

• C07K 14/46 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates

Abstract

The present invention relates to new compounds for treating, preventing or inhibiting a parasitic disease, preferably toxoplasmosis in a subject, the method for preparing thereof.

IPC Classes  ?

• C07C 259/10 - Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of six-membered aromatic rings
• C07C 311/19 - Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
• C07C 311/21 - Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
• C07D 277/30 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• A61K 31/16 - Amides, e.g. hydroxamic acids
• A61K 31/18 - Sulfonamides
• A61K 31/426 - 1,3-Thiazoles
• A61P 33/02 - Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis

Abstract

The present invention relates to peptides and methods for the detection of anti-leishmanial antibodies in individuals suspected of infection with the protozoan parasite of the genus Leishmania, especially infection with a South American strain causing the American Tegumentary Leishmaniasis (ATL).

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

The present invention relates to capsules enclosing nucleic acid fragments of variable controlled sizes suitable to be used as an internal standard in micro-electrophoresis assays, such as single cell micro-electrophoresis assays.

IPC Classes  ?

• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
• G01N 33/96 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood or serum control standard

Abstract

The invention relates to a use for preventing or treating a dengue infection, consisting of a putative 34 kDa family secreted salivary protein (GenBank accession number Q1HRW0 AEDAE) of Aedes aegypti.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61P 31/12 - Antivirals
• A61K 35/64 - Insects, e.g. bees, wasps or fleas

Abstract

The present invention relates to new arylaminoalcohol derivatives of formula (I), and to a method for the preparation of such compounds: The invention also relates to the use of these compounds as medicaments, and in particular for the prevention and/or the treatment of parasitic diseases caused by apicomplexan parasites such as malaria and toxoplasmosis. Finally, the invention relates to pharmaceutical compositions containing such compounds of formula (I) as active principles.

IPC Classes  ?

• C07D 409/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 211/70 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• C07D 211/98 - Nitrogen atom
• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
• A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
• A61P 31/18 - Antivirals for RNA viruses for HIV
• A61P 33/02 - Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
• A61P 33/06 - Antimalarials

Abstract

The present invention relates to new arylaminoalcohol derivatives of formula (I), and to a method for the preparation of such compounds: I The invention also relates to the use of these compounds as medicaments, and in particular for the prevention and/or the treatment of parasitic diseases caused by apicomplexan parasites such as malaria and toxoplasmosis. Finally, the invention relates to pharmaceutical compositions containing such compounds of formula (I) as active principles.

IPC Classes  ?

• C07D 409/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 211/70 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• C07D 211/98 - Nitrogen atom
• A61P 33/02 - Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
• A61P 33/06 - Antimalarials
• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
• A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
• A61P 31/18 - Antivirals for RNA viruses for HIV

Abstract

The invention concerns a solid state fermentation (SSF) device, characterised in that it comprises - a rigid outer mould (1) - an inner portion forming a removable single-use fermentation chamber (2) formed from a flexible material and comprising 2 portions, - the lower portion (8), or lower chamber, which is harder and has a shape almost identical to that of the container (3), - the upper portion (10) or upper chamber intended to enclose the material that is to be fermented, formed from a more flexible material, the useful volume thereof being greater than that of the lower portion, - aeration means being provided between these two portions.

IPC Classes  ?

• C12M 1/16 - Apparatus for enzymology or microbiology containing, or adapted to contain, solid media
• C12M 1/00 - Apparatus for enzymology or microbiology

Abstract

The present invention relates to a compound of the following formula (I) or to a salt, hydrate, or pharmaceutically acceptable solvate thereof, in which R is a monosaccharide or disaccharide residue. The hydroxyl functions of the monosaccharide or disaccharide residue are, independently, optionally substituted for a (C1-C6) alkyl or -C(O)NH- (C1-C6) alkyl group. The invention also relates to the method for preparing said compound, to a pharmaceutical composition containing same, and to the use thereof as a drug, particularly for cancer treatment.

IPC Classes  ?

• C07H 17/08 - Hetero rings containing eight or more ring members, e.g. erythromycins
• A61K 31/70 - CarbohydratesSugarsDerivatives thereof
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Abstract

The present invention relates to combinations of polypeptides or of polynucleotides corresponding to a specific region of the N-terminal portion of the VAR2CSA protein of different parasitic families or lines of Plasmodium falciparum, and to their use in the prevention of pregnancy-associated malaria. The invention also relates to immunogenic compositions and to vaccines useful for preventing malaria in pregnant women.

IPC Classes  ?

• A61K 39/015 - Hemosporidia antigens, e.g. Plasmodium antigens

Abstract

The invention relates to monoepitopic or polyepitopic peptidic compounds of sequence SEQ ID N° 1 to 16 and to the analogous, mutein and homologous derivatives thereof, for the prevention and treatment of Leishmaniases in mammals and especially in humans, canines, felines and equines. The invention especially relates to vaccines comprising said peptidic compounds in conditions ensuring immunisation leading to effective protection of the vaccinated human or animal against at least one Leishmania.

IPC Classes  ?

• A61K 39/008 - Leishmania antigens

Abstract

The present invention relates to acetylsalicylic acid or a salt thereof, at a concentration comprised between 200 and 4800 μΜ, for use in the prevention and/or treatment of diabetic wounds.

IPC Classes  ?

• A61K 31/60 - Salicylic acidDerivatives thereof
• A61P 9/14 - VasoprotectivesAntihaemorrhoidalsDrugs for varicose therapyCapillary stabilisers
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The present invention concerns two sets of mini- and micro-satellite molecular markers, and the use thereof to study the genetic diversity and/or identify the genotypes of date palms. The invention also concerns method for identifying date palm cultivars using these sets of molecular markers, and kits for implementing these methods.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

The invention relates to the oligonucleotide of sequence SEQ ID N°1 : 5'- CTAGAGATCCCTCAGA - 3 ', and the complementary sequence thereof of sequence SEQ ID N° 2: 5 '- TCTGAGGGATCTCT AG - 3 ' useful as probes to detect and quantify all HIV-1 circulating forms and their precursors SIVcpz/SIVgor.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage

Abstract

The present invention relates to a method for determining whether an overweight subject has a reduced gut bacterial diversity. The said method comprises detecting the presence or absence in a gut DNA sample of at least one gene of at least one bacterial species of Table 1 or Table 2, respectively.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

The present invention relates to molecular markers and to the use thereof for distinguishing male date palm plants from female date palm plants. The invention also relates to a method for identifying the sex of date palm plants using these molecular markers, and to a kit for carrying out the method.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

The present invention relates to the use of 4-phenylbutyric acid, or one of the salts thereof, for improving the resistance of plants to harmful biological organisms, in particular to bacteria, viruses, and nematodes, and for inhibiting the cell death of the hypersensitive response induced by such harmful biological organisms. The present invention also relates to the use of 4-phenylbutyric acid, or one of the salts thereof, as an antimicrobial agent for preventing or treating plant diseases caused by phytopathogens.

IPC Classes  ?

• A01N 37/10 - Aromatic or araliphatic carboxylic acids, or thio-analogues thereofDerivatives thereof

Abstract

The present invention concerns the use of at least one seed or plant chosen from the Lamiaceae family and precultured in an area of ground for revegetation, in particular an area of ground for revegetation having a volume of approximately 0.5L, in particular for approximately 3 to 6 months, in particular 5 months, to produce a precultured plant, said precultured plant being uprooted from the area of ground after said precultivation, for the multiplication of mycorrhizal fungi and for improving the growth of at least one seed or plant of forest and/or fruit species in said ground for revegetation.

IPC Classes  ?

• A01C 21/00 - Methods of fertilising

Abstract

The present invention relates to Clem2, the first active LTR retrotransposon identified in the coffee plant, and its use in the clonal and/or varietal identification of coffee plants. The invention provides PCR primers, kits comprising such PCR primers, and methods using such kits and/or PCR primers for the clonal and/or varietal identification of several coffee species. The primers, kits and methods are particularly useful for coffee certification and traceability.

IPC Classes  ?

• A01H 1/04 - Processes of selection
• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells

Abstract

The invention relates to a composition of lemon peel essential oil useful as a growth promoter in poultry, said composition comprises at least 16.84 to 46.12 % d-limonene; 5.67 to 19.86 % y-terpinene; 4.27 to 12.13 % terpinolene; 4.60 to 14.75 % p-menth-1-3n-8-ol; among other components. The invention also relates to a food supplement for poultry, which comprises 1 kg per metric ton of feed of the said essential oil composition.

IPC Classes  ?

• A23K 1/14 - from vegetable materials, e.g. potatoes or roots without ensilaging
• A23K 1/16 - supplemented with accessory food factors; Salt blocks
• A23K 1/18 - specially adapted for particular animals
• A61K 36/752 - Citrus, e.g. lime, orange or lemon

Abstract

The present invention relates to the reforestation of a soil area with co culture of tree species with nurse plants.

IPC Classes  ?

• A01G 1/04 - Cultivation of mushrooms (composts or fertilisers for cultivating mushrooms C05)
• A01H 17/00 - Symbiotic or parasitic combinations including one or more new plants, e.g. mycorrhiza

Abstract

The invention relates to a protective device (15) for protecting a fish (2) caught on a hook, said protective device (15) comprising a body (16) and a plurality of elongate protective elements (17), wherein the plurality of protective elements (17) includes first protective elements (17a) having a first buoyancy for being deployed by moving away from the body (16) above the hook and second protective elements (17b) having a second buoyancy, which is less than the first buoyancy, for surrounding the hook.

IPC Classes  ?

• A01K 91/06 - Apparatus on lines not otherwise provided for, e.g. automatic hookers
• A01K 91/18 - Trotlines, longlinesAccessories therefor, e.g. baiting devices, lifters or setting reelers

Abstract

La present invention relates to the use of a nucleic sequence allowing the synthesis of Gh ERF-IIa, Gh ERF-IIb or Gh ERF-IIc in a plant in order to induce, in the plant, an overproduction or accumulation of jasmonic acid and/or OPDA. The accumulation of jasmonic acid and/or OPDA confers, in particular, to the transformed plant an improved resistance to bioagressors. The nucleic sequences, transformation methods and transformed plants according to the invention may also been used for the production of pharmaceutically important secondary metabolites whose synthesis is induced by jasmonates.

IPC Classes  ?

• A01H 5/00 - Angiosperms, i.e. flowering plants, characterised by their plant partsAngiosperms characterised otherwise than by their botanic taxonomy
• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
• A01N 63/02 - Substances produced by, or obtained from, microorganisms or animals

Abstract

The present invention provides a method for determining the amino acid polymorphisms of heavy gamma chain of immunoglobulins G by a proteomic approach. This method distinguishes the immunoglobulins of the mother and those of the newborn in a blood sample obtained during the first months of the child's life. The invention also relates to the use of this method in the early diagnosis of vertically transmitted diseases in the neonate. The invention also provides peptides distinctive of G3m and IGHG3 alleles, and a kit comprising said peptides.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The invention relates to an apparatus for physically analyzing soil or another natural, organized medium, comprising a sample changer (100) capable of receiving at least two soil-sample holders (1), said sample changer having a means for placing each sample holder and the sample (2) thereof in a measurement area, in turns, according to a cycle repeated over time, the apparatus including: a means for measuring the size of said samples; a means for measuring the potential of said samples containing water; and a means for measuring the weight of said samples, wherein all of said measuring means are grouped together in said measurement area so as to be simultaneously used implemented for a given sample when the latter is placed in said measurement area. The shrinkage curve and the water potential curve, which are obtained from said measurements, represent the change, over time, in the status of the water and structure of the soil sample during the drying thereof, and can be used to determine the hydrostructural characteristics of the soil.

IPC Classes  ?

• G01N 33/24 - Earth materials
• G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups Handling materials therefor

Abstract

A method of quantitative characterisation of an organised natural medium such as a soil, comprising steps consisting of: • a) - taking a sample of said natural medium; • b) - saturating the sample with water; • c) - placing the sample in an recipient at a set temperature suitable for causing gradual desiccation, from the saturated state to the dry state of said sample, and measuring the dimensions, water potential, and mass thereof, said measurements being taken from the sample simultaneously and repeated at predetermined time intervals throughout the desiccation period; • d) - plotting the shrinkage curve (V, W) and the water potential curve (h, W); and • e) - analysing all of said curves {V, W) and {h, W) in order to determine the parameters characterising the thermodynamic balance status of said structured medium with any water content, said analysis comprising at least one operation of adjusting said measured curves with the theoretical curves corresponding to the thermodynamic equations of the system as a function of water content W. The method provides a reliable and generic tool for predicting the long-term impact of industrial products on soils and for managing natural resources appropriately.

IPC Classes  ?

• G01N 33/24 - Earth materials

Abstract

Composition for anti-mosquito use comprising the combination of at least one fertilizer of NPK type with at least one anti-mosquito larvicide compound.

IPC Classes  ?

• A01P 7/04 - Insecticides
• A01N 59/00 - Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
• A01N 59/08 - Alkali metal chloridesAlkaline earth metal chlorides
• A01N 59/26 - PhosphorusCompounds thereof
• A01N 43/22 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom with one hetero atom rings with more than six members
• A01N 43/40 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
• A01N 47/34 - Ureas or thioureas containing the groups N—CO—N or N—CS—N containing the groups , e.g. biuretThio-analogues thereofUrea-aldehyde condensation products
• A01N 49/00 - Biocides, pest repellants or attractants, or plant growth regulators containing compounds containing the group wherein m+n≥1, both X together may also mean —Y— or a direct carbon-to-carbon bond, and the carbon atoms marked with an asterisk are not part of any ring system other than that which may be formed by the atoms X, the carbon atoms in square brackets being part of any acyclic or cyclic structure, or the group wherein A means a carbon atom or Y, n ≥ 0, and not more than one of these carbon atoms being a member of the same ring system, e.g. juvenile insect hormones or mimics thereof
• A01N 63/00 - Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates

Abstract

The present invention is related to a therapeutic mucosal or intradermal or intraepithelial vaccine composition for use in a method for treating an infection by a HIV virus in a human in need thereof, comprising: - an antigen made of inactivated autologous HIV virus; and - a tolerogenic adjuvant which, when combined to said antigen in said therapeutic vaccine composition, induces and, preferably, maintains immunotolerance to said HIV virus in said human, thereby treating said infection in said human. More precisely, the therapeutic vaccine compositions of the present invention produce a virus-specific non-cytotoxic MHC-lb/E-restricted suppressive CD8+ T cell- induced immunotolerance ("Ts" immunotolerance for "T suppressive" immunotolerance) upon mucosal or intradermal or intraepithelial administration to humans. "Ts" immunotolerance is associated with the suppression of viral replication. The present invention also relates to a method for treating an infection by a HIV virus in a human in need thereof, comprising at least the step of mucosally or intradermally or intraepithelial administering a therapeutic vaccine composition as defined above to said human.

IPC Classes  ?

• A61K 39/09 - Streptococcus
• A61K 39/21 - Retroviridae, e.g. equine infectious anemia virus
• A61K 39/295 - Polyvalent viral antigensMixtures of viral and bacterial antigens
• A61P 31/18 - Antivirals for RNA viruses for HIV

Abstract

The present invention relates to pharmaceutical compositions comprising a mixture of a specific HIV antigen and a non-pathogenic living bacterium. Said specific HIV antigen comprises one or more epitopes from Gag and/or Pol proteins and is preferably under a particulate form. Said bacterium is preferably Lactobacillus plantarum. These compositions are useful for preventing and/or treating an HIV disease in humans.

IPC Classes  ?

• A61K 39/09 - Streptococcus
• A61K 39/21 - Retroviridae, e.g. equine infectious anemia virus
• A61K 39/295 - Polyvalent viral antigensMixtures of viral and bacterial antigens
• A61P 31/18 - Antivirals for RNA viruses for HIV

Abstract

The invention relates to Simalikalactone E (SkE) to be used for preventing and/or treating cancers.

IPC Classes  ?

• A61K 31/335 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
• A61K 31/366 - Lactones having six-membered rings, e.g. delta-lactones
• A61P 35/00 - Antineoplastic agents

Abstract

Underwater device (10) providing propulsion and capturing images of a seabed, comprising a hydrodynamic thruster (3) fitted with handles (39) held by a diver (90), a support (2) fixed to the hydrodynamic thruster, a photo/video camera device (4; 7) for capturing images and which is fixed to said support and aimed towards the seabed, said support being equipped with at least two generators of laser beams (5; 5') aimed at the field of view of the photo/video camera device, each generator being designed to generate a laser beam (51; 53, 54) that produces a light spot on the seabed.

IPC Classes  ?

• B63C 11/46 - Divers' sleds or like craft, i.e. craft on which man in diving-suit rides
• B63C 11/48 - Means for searching for underwater objects

Abstract

The present invention relates to novel fungal inocula compositions, to the method for preparing same, and to the use thereof for enhancing culture growth. (No drawings)

IPC Classes  ?

• A01N 63/04 - Microbial fungi;  Substances produced thereby or obtained therefrom
• A01N 59/26 - PhosphorusCompounds thereof
• A01N 25/12 - Powders or granules
• A01N 25/26 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests in coated particulate form
• A01P 21/00 - Plant growth regulators
• C05F 11/08 - Organic fertilisers containing added bacterial cultures, mycelia or the like
• A01G 7/00 - Botany in general

Abstract

The present invention relates to a method of treating, preventing or inhibiting parasitic disease, in particular leishmaniasis or trypanosomiasis in a subject, by a compound of formula (1): R2-A-R1 wherein: - A represents a group chosen from a phenyl, a triazolyl, and a thienyl, - R1 represents -CO-CH2OH or -CO-NHOH, - R2 is chosen from H, triazolyl, methyltriazolyl, -CONHR3, -CH2-CONHR3, - 'NHS02NHR3, -CH2-NHSO2NHR3, wherein R3 represents H, a (C1-C8) alkyl group, an aryl group, a (C3-C8) cycloalkyl group, a heterocyclic group, or a heteroaryl group. Or a pharmaceutically acceptable salt thereof.

IPC Classes  ?

• C07C 49/172 - Saturated compounds containing keto groups bound to acyclic carbon atoms containing hydroxy groups containing rings
• C07C 235/34 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
• A61P 33/02 - Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
• A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
• A61K 31/12 - Ketones
• C07C 259/10 - Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of six-membered aromatic rings

Abstract

The present invention relates to specific regions of the N-terminal portion of the VAR2CSA protein and to the use of such specific regions in the prevention of pregnancy-associated malaria. The invention also provides immunogenic compositions and vaccines that are useful for preventing malaria in pregnant women.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61K 39/015 - Hemosporidia antigens, e.g. Plasmodium antigens
• A61P 33/06 - Antimalarials
• C07K 14/445 - Plasmodium

Abstract

The present invention relates to methods for obtaining a transgenic plant that overproduces jasmonic acid, and optionally OPDA, a jasmonic acid precursor. Said methods include transforming the plant using a nucleic acid encoding ORA47. The accumulation of jasmonic acid confers in particular to the transformed plant an improved resistance to pathogenic agents. The transgenic plants obtained may also be used for the production of pharmaceutically important secondary metabolites whose synthesis is induced by jasmonates.

IPC Classes  ?

• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells

Abstract

The invention targets a composition for the inoculation in a plant of agrobacteria transfected by expression vectors, for the purposes of producing in the plant a protein of interest or a derivative of this protein, by deletion or by mutation, characterized in that it comprises - agrobacteria transfected by at least one expression vector, comprising a nucleotide sequence insert coding for said protein or a derivative of this protein, and - agrobacteria transfected by a plurality of expression vectors each comprising at least one nucleotide sequence insert coding for proteins having a silencing suppressor effect.

IPC Classes  ?

• C07K 14/44 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from protozoa
• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells